Adding targeted radiation to standard lung cancer treatment

The OBLITERATE trial is testing whether adding locally ablative therapies—focused treatments that use radiation or heat to destroy specific tumors—can help lung cancer patients stay on their current systemic (whole-body) cancer treatment longer. Researchers will track whether this combination approach keeps your disease stable for at least 3 months and helps you avoid switching medications.

When lung cancer starts spreading despite treatment, doctors sometimes have to change your medication entirely. This trial explores whether targeting just the few new tumors with focused radiation or heat, while continuing your current systemic therapy, might let you stay on a treatment that was already working for you.